Website intended for a NZ health professional readership
We are on our summer break and the editorial office is closed until 13 January. In the meantime, please enjoy our Summer Hiatus series, in which our journalists curate an eclectic mix from our news and clinical archives throughout the year, The Conversation and other publications we share content with. Please note the comment function has been turned off while we are away. Happy reading!
This article was first published online on 14 August 2024.
Pharmacist prescriber Leanne Te Karu highlights the importance of diagnosing chronic kidney disease early, which involves incorporating renal screening into cardiovascular risk assessments
1. Walker C, Reid S, White C, et al. Management of chronic kidney disease for Māori in Aotearoa, New Zealand: a summary of clinical practice guidelines. N Z Med J 2024;137(1594):62–68.
2. Ortiz A, Wanner C, Gansevoort R. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association. Nephrol Dial Transplant 2023;38(3):527–31.
3. Mayne KJ, Hanlon P, Lees JS. Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines. Diabetes Obes Metab 2024; 3 May online.
4. Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012;157(4):263–75.
5. London Kidney Network. CKD in Primary Care: new approaches to reduce inequalities and save lives. September 2022.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
